Which has stronger earnings and valuation, EXEL or CELC?

Exelixis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.30 $782.57M $3.18 18.56 Celcuity N/A N/A -$177.04M -$4.30 N/A

Is EXEL or CELC more profitable?

Exelixis has a net margin of 35.33% compared to Celcuity's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Celcuity N/A -350.78% -41.54%

Does the media prefer EXEL or CELC?

In the previous week, Celcuity had 1 more articles in the media than Exelixis. MarketBeat recorded 10 mentions for Celcuity and 9 mentions for Exelixis. Exelixis' average media sentiment score of 0.63 beat Celcuity's score of 0.04 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celcuity 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CELC or ASND?

In the previous week, Celcuity had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 10 mentions for Celcuity and 2 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.25 beat Celcuity's score of 0.04 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, CELC or SMMT?

Celcuity is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$4.30 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is CELC or SMMT more profitable?

Summit Therapeutics' return on equity of -168.94% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -350.78% -41.54% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor CELC or SMMT?

In the previous week, Celcuity had 3 more articles in the media than Summit Therapeutics. MarketBeat recorded 10 mentions for Celcuity and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.26 beat Celcuity's score of 0.04 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 0 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CELC or BBIO?

In the previous week, BridgeBio Pharma had 2 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for BridgeBio Pharma and 10 mentions for Celcuity. BridgeBio Pharma's average media sentiment score of 0.49 beat Celcuity's score of 0.04 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 3 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CELC or HALO?

In the previous week, Halozyme Therapeutics had 12 more articles in the media than Celcuity. MarketBeat recorded 22 mentions for Halozyme Therapeutics and 10 mentions for Celcuity. Halozyme Therapeutics' average media sentiment score of 0.61 beat Celcuity's score of 0.04 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 1 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Halozyme Therapeutics 9 Very Positive mention(s) 6 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Celcuity (CELC) Competitors

$67.94 +0.07 (+0.10%)

Closing price 04:00 PM Eastern

Extended Trading

$67.94 0.00 (0.00%)

As of 07:42 PM Eastern

Compare

CELC vs. EXEL, ASND, SMMT, BBIO, and HALO

Should you buy Celcuity stock or one of its competitors? Celcuity's main competitors and comparable companies include Exelixis (EXEL), Ascendis Pharma A/S (ASND), Summit Therapeutics (SMMT), BridgeBio Pharma (BBIO), and Halozyme Therapeutics (HALO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Celcuity compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Celcuity (NASDAQ:CELC) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, media sentiment, profitability, valuation, earnings and institutional ownership.

Exelixis has a beta of 0.47, meaning that its share price is 53% less volatile than the broader market. Comparatively, Celcuity has a beta of 0.1, meaning that its share price is 90% less volatile than the broader market.

Exelixis has a net margin of 35.33% compared to Celcuity's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Celcuity	N/A	-350.78%	-41.54%

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 63.3% of Celcuity shares are owned by institutional investors. 2.6% of Exelixis shares are owned by insiders. Comparatively, 13.3% of Celcuity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Exelixis presently has a consensus price target of $50.36, suggesting a potential downside of 14.68%. Celcuity has a consensus price target of $154.25, suggesting a potential upside of 127.27%. Given Celcuity's stronger consensus rating and higher possible upside, analysts plainly believe Celcuity is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Exelixis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.30	$782.57M	$3.18	18.56
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A

In the previous week, Celcuity had 1 more articles in the media than Exelixis. MarketBeat recorded 10 mentions for Celcuity and 9 mentions for Exelixis. Exelixis' average media sentiment score of 0.63 beat Celcuity's score of 0.04 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celcuity	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Exelixis beats Celcuity on 11 of the 16 factors compared between the two stocks.

How does Celcuity compare to Ascendis Pharma A/S?

Celcuity (NASDAQ:CELC) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, dividends, analyst recommendations and institutional ownership.

Celcuity has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.38, suggesting that its share price is 62% less volatile than the broader market.

Celcuity has higher earnings, but lower revenue than Ascendis Pharma A/S. Celcuity is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Ascendis Pharma A/S	$814.57M	17.05	-$258M	$12.89	17.28

Celcuity presently has a consensus price target of $154.25, suggesting a potential upside of 127.27%. Ascendis Pharma A/S has a consensus price target of $310.75, suggesting a potential upside of 39.54%. Given Celcuity's higher possible upside, research analysts plainly believe Celcuity is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

63.3% of Celcuity shares are held by institutional investors. 13.3% of Celcuity shares are held by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Ascendis Pharma A/S has a net margin of 70.99% compared to Celcuity's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

In the previous week, Celcuity had 8 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 10 mentions for Celcuity and 2 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.25 beat Celcuity's score of 0.04 indicating that Ascendis Pharma A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Ascendis Pharma A/S beats Celcuity on 12 of the 16 factors compared between the two stocks.

How does Celcuity compare to Summit Therapeutics?

Celcuity (NASDAQ:CELC) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

Celcuity has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, meaning that its stock price is 251% less volatile than the broader market.

Summit Therapeutics' return on equity of -168.94% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Summit Therapeutics	N/A	-168.94%	-141.92%

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 83.5% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Celcuity presently has a consensus target price of $154.25, indicating a potential upside of 127.27%. Summit Therapeutics has a consensus target price of $28.61, indicating a potential upside of 66.61%. Given Celcuity's stronger consensus rating and higher probable upside, research analysts plainly believe Celcuity is more favorable than Summit Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

In the previous week, Celcuity had 3 more articles in the media than Summit Therapeutics. MarketBeat recorded 10 mentions for Celcuity and 7 mentions for Summit Therapeutics. Summit Therapeutics' average media sentiment score of 0.26 beat Celcuity's score of 0.04 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	0 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celcuity is trading at a lower price-to-earnings ratio than Summit Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

Summary

Celcuity beats Summit Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Celcuity compare to BridgeBio Pharma?

Celcuity (NASDAQ:CELC) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

Celcuity currently has a consensus price target of $154.25, indicating a potential upside of 127.27%. BridgeBio Pharma has a consensus price target of $105.42, indicating a potential upside of 62.09%. Given Celcuity's higher possible upside, analysts clearly believe Celcuity is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.83

Celcuity has a beta of 0.1, meaning that its stock price is 90% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market.

Celcuity has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
BridgeBio Pharma	-97.03%	N/A	-61.19%

Celcuity has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Celcuity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
BridgeBio Pharma	$502.08M	25.32	-$724.93M	-$3.57	N/A

In the previous week, BridgeBio Pharma had 2 more articles in the media than Celcuity. MarketBeat recorded 12 mentions for BridgeBio Pharma and 10 mentions for Celcuity. BridgeBio Pharma's average media sentiment score of 0.49 beat Celcuity's score of 0.04 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	3 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BridgeBio Pharma beats Celcuity on 9 of the 14 factors compared between the two stocks.

How does Celcuity compare to Halozyme Therapeutics?

Celcuity (NASDAQ:CELC) and Halozyme Therapeutics (NASDAQ:HALO) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, earnings, valuation and risk.

Celcuity has a beta of 0.1, indicating that its share price is 90% less volatile than the broader market. Comparatively, Halozyme Therapeutics has a beta of 0.88, indicating that its share price is 12% less volatile than the broader market.

Halozyme Therapeutics has a net margin of 24.86% compared to Celcuity's net margin of 0.00%. Halozyme Therapeutics' return on equity of 260.98% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Halozyme Therapeutics	24.86%	260.98%	23.91%

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 97.8% of Halozyme Therapeutics shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 2.5% of Halozyme Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Halozyme Therapeutics had 12 more articles in the media than Celcuity. MarketBeat recorded 22 mentions for Halozyme Therapeutics and 10 mentions for Celcuity. Halozyme Therapeutics' average media sentiment score of 0.61 beat Celcuity's score of 0.04 indicating that Halozyme Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	1 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Halozyme Therapeutics	9 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Celcuity presently has a consensus target price of $154.25, indicating a potential upside of 127.27%. Halozyme Therapeutics has a consensus target price of $94.00, indicating a potential downside of 14.42%. Given Celcuity's stronger consensus rating and higher possible upside, analysts clearly believe Celcuity is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Halozyme Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.67

Halozyme Therapeutics has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Halozyme Therapeutics	$1.40B	8.93	$316.89M	$3.35	32.79

Summary

Halozyme Therapeutics beats Celcuity on 11 of the 15 factors compared between the two stocks.

Get Celcuity News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CELC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CELC vs. The Competition

Export

Metric	Celcuity	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$3.32B	$3.84B	$7.16B	$13.21B
Dividend Yield	N/A	3.66%	2.53%	20.71%
P/E Ratio	-15.80	13.42	274.13	26.16
Price / Sales	N/A	1,225.48	587.04	94.78
Price / Cash	N/A	116.56	76.38	53.09
Price / Book	31.31	17.17	11.21	6.34
Net Income	-$177.04M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-5.77%	-1.20%	-0.84%	-1.39%
1 Month Performance	-24.58%	-9.68%	-5.42%	-4.31%
1 Year Performance	37.34%	10.09%	4.38%	-0.35%

Celcuity Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CELC Celcuity	2.9362 of 5 stars	$67.94 +0.1%	$154.25 +127.0%	+37.1%	$3.32B	N/A	N/A	155
EXEL Exelixis	2.4643 of 5 stars	$57.85 -0.9%	$50.29 -13.1%	+52.7%	$14.35B	$2.32B	18.21	1,077	Trending News Analyst Forecast Analyst Revision
ASND Ascendis Pharma A/S	4.7897 of 5 stars	$227.59 -1.1%	$310.75 +36.5%	+6.0%	$14.20B	$814.57M	17.66	1,189
SMMT Summit Therapeutics	2.3488 of 5 stars	$16.43 +6.1%	$28.22 +71.8%	-26.4%	$13.14B	N/A	N/A	265	High Trading Volume
BBIO BridgeBio Pharma	3.9436 of 5 stars	$66.74 +0.2%	$102.61 +53.8%	+17.6%	$13.05B	$502.08M	N/A	839	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CELC) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celcuity (CELC) Competitors

CELC vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Celcuity compare to Exelixis?

Summary

How does Celcuity compare to Ascendis Pharma A/S?

Summary

How does Celcuity compare to Summit Therapeutics?

Summary

How does Celcuity compare to BridgeBio Pharma?

Summary

How does Celcuity compare to Halozyme Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC vs. The Competition

Celcuity Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celcuity (CELC) Competitors

CELC vs. EXEL, ASND, SMMT, BBIO, and HALO

How does Celcuity compare to Exelixis?

Which has more volatility and risk, EXEL or CELC?

Is EXEL or CELC more profitable?

Do institutionals & insiders hold more shares of EXEL or CELC?

Do analysts rate EXEL or CELC?

Which has stronger earnings and valuation, EXEL or CELC?

Does the media prefer EXEL or CELC?

Summary

How does Celcuity compare to Ascendis Pharma A/S?

Which has more volatility & risk, CELC or ASND?

Which has stronger valuation and earnings, CELC or ASND?

Do analysts rate CELC or ASND?

Do institutionals and insiders have more ownership in CELC or ASND?

Is CELC or ASND more profitable?

Does the media refer more to CELC or ASND?

Summary

How does Celcuity compare to Summit Therapeutics?

Which has more risk & volatility, CELC or SMMT?

Is CELC or SMMT more profitable?

Do institutionals & insiders have more ownership in CELC or SMMT?

Do analysts prefer CELC or SMMT?

Does the media favor CELC or SMMT?

Which has stronger earnings and valuation, CELC or SMMT?

Summary

How does Celcuity compare to BridgeBio Pharma?

Do analysts prefer CELC or BBIO?

Which has more risk and volatility, CELC or BBIO?

Is CELC or BBIO more profitable?

Which has better valuation and earnings, CELC or BBIO?

Does the media favor CELC or BBIO?

Do insiders & institutionals have more ownership in CELC or BBIO?

Summary

How does Celcuity compare to Halozyme Therapeutics?

Which has more volatility & risk, CELC or HALO?

Is CELC or HALO more profitable?

Do insiders and institutionals have more ownership in CELC or HALO?

Does the media favor CELC or HALO?

Do analysts recommend CELC or HALO?

Which has better earnings and valuation, CELC or HALO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CELC vs. The Competition

Celcuity Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools